利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

50 条记录 (耗时 0.035 秒)

    1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
    31.
    发明授权
    1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors 失效
    1,2,3-三唑衍生物可用作烟碱乙酰胆碱受体的调节剂

    公开(公告)号：US08110588B2

    公开(公告)日：2012-02-07

    申请号：US12672252

    申请日：2008-08-06

    申请人： Antonio Nardi ,  Jeppe Kejser Christensen ,  Dan Peters ,  Gunnar M. Olsen ,  Tino Dyhring

    发明人： Antonio Nardi ,  Jeppe Kejser Christensen ,  Dan Peters ,  Gunnar M. Olsen ,  Tino Dyhring

    IPC分类号： C07D413/10 ,  C07D249/06 ,  A61K31/4192 ,  A61K31/4245

    CPC分类号： C07D249/06 ,  C07D413/04

    摘要： This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及新的1,2,3-三唑衍生物，其被发现是烟碱乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists
    33.
    发明申请
    3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists 有权
    3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物作为烟碱乙酰胆碱受体激动剂

    公开(公告)号：US20090005388A1

    公开(公告)日：2009-01-01

    申请号：US12087004

    申请日：2007-02-09

    申请人： Dan Peters ,  Daniel B. Timmermann ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Jeppe Kejser Christensen

    发明人： Dan Peters ,  Daniel B. Timmermann ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Jeppe Kejser Christensen

    IPC分类号： A61K31/4985 ,  C07D471/08 ,  A61P25/00

    CPC分类号： C07D471/08

    摘要： This invention relates to novel 3,9-diazabicyclo[3.3.1]nonane derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及在烟碱乙酰胆碱受体和单胺受体和转运蛋白的调节剂中被发现是胆碱能配体的新的3,9-二氮杂双环[3.3.1]壬烷衍生物。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    34.
    发明申请
    N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS 有权
    N-乙酰胆碱衍生物有用作为非线性乙酰胆碱受体的调节剂

    公开(公告)号：US20100280092A1

    公开(公告)日：2010-11-04

    申请号：US12743836

    申请日：2008-11-19

    申请人： Antonio Nardi ,  Jeppe Kejser Christensen ,  Dan Peters ,  Tino Dyhring

    发明人： Antonio Nardi ,  Jeppe Kejser Christensen ,  Dan Peters ,  Tino Dyhring

    IPC分类号： A61K31/405 ,  C07D209/20 ,  A61P25/00 ,  A61P25/28 ,  A61P25/24 ,  A61P25/22 ,  A61P9/12 ,  A61P9/06 ,  A61P29/00 ,  A61P25/30

    CPC分类号： C07D209/18 ,  C07D209/30 ,  C07D409/12

    摘要： This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及N-酰腙衍生物，其被发现可用作烟碱型乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或病症多种多样 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors
    36.
    发明授权
    N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors 有权
    N-酰腙衍生物可用作烟碱乙酰胆碱受体的调节剂

    公开(公告)号：US08101649B2

    公开(公告)日：2012-01-24

    申请号：US12743836

    申请日：2008-11-19

    申请人： Antonio Nardi ,  Jeppe Kejser Christensen ,  Dan Peters ,  Tino Dyhring

    发明人： Antonio Nardi ,  Jeppe Kejser Christensen ,  Dan Peters ,  Tino Dyhring

    IPC分类号： A61K31/405 ,  C07D209/20 ,  A61P25/00 ,  A61P25/28 ,  A61P25/24 ,  A61P25/22 ,  A61P9/12 ,  A61P9/06 ,  A61P29/00 ,  A61P25/30

    CPC分类号： C07D209/18 ,  C07D209/30 ,  C07D409/12

    摘要： This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及N-酰腙衍生物，其被发现可用作烟碱型乙酰胆碱受体的调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。